The DOI matches its Crossref record; 256 of the 256 references it cites were found in a registry or an index.
CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges
Open accessAbstract
Chimeric antigen receptor T (CAR-T) cell therapy represents a major breakthrough in cancer treatment, and it has achieved unprecedented success in hematological malignancies, especially in relapsed/refractory (R/R) B cell malignancies. At present, CD19 and BCMA are the most common targets in CAR-T cell therapy, and numerous novel therapeutic targets are being explored. However, the adverse events related to CAR-T cell therapy might be serious or even life-threatening, such as cytokine release syndrome (CRS), CAR-T-cell-related encephalopathy syndrome (CRES), infections, cytopenia, and CRS-related coagulopathy. In addition, due to antigen escape, the limited CAR-T cell persistence, and immunosuppressive tumor microenvironment, a considerable proportion of patients relapse after CAR-T cell therapy. Thus, in this review, we focus on the progress and challenges of CAR-T cell therapy in hematological malignancies, such as attractive therapeutic targets, CAR-T related toxicities, and resistance to CAR-T cell therapy, and provide some practical recommendations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Parrondo, R. D., Sam, K. T., Rasheed, A., Alegria, V. R., Sher, T., Roy, V., Chanan-Khan, A. A., & Ailawadhi, S. (2022) · Blood Cancer Journal · doi:10.1038/s41408-022-00662-0 · Cited by 10
RetractedAxicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Neelapu, S. S., Locke, F. L., Bartlett, N. L., Lekakis, L. J., Miklos, D. B., Jacobson, C. A., Braunschweig, I., Oluwole, O. O., Siddiqi, T., Lin, Y., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707447 · Cited by 6,030
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
Maude, S. L., Laetsch, T. W., Buechner, J., Rives, S., Boyer, M., Bittencourt, H., Bader, P., Verneris, M. R., Stefanski, H. E., Myers, G. D., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1709866 · Cited by 5,735
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
Rajkumar, S. V., Dimopoulos, M. A., Palumbo, A., Blade, J., Merlini, G., Mateos, M.-V., Kumar, S., Hillengass, J., Kastritis, E., Richardson, P., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70442-5 · Cited by 4,978
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Schuster, S. J., Bishop, M. R., Tam, C. S., Waller, E. K., Borchmann, P., McGuirk, J. P., Jäger, U., Jaglowski, S., Andreadis, C., Westin, J. R., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1804980 · Cited by 4,112
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Abramson, J. S., Palomba, M. L., Gordon, L. I., Lunning, M. A., Wang, M., Arnason, J., Mehta, A., Purev, E., Maloney, D. G., Andreadis, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31366-0 · Cited by 2,430
Locke, F. L., Ghobadi, A., Jacobson, C. A., Miklos, D. B., Lekakis, L. J., Oluwole, O. O., Lin, Y., Braunschweig, I., Hill, B. T., Timmerman, J. M., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30864-7 · Cited by 2,286
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors
Liu, E., Marin, D., Banerjee, P., Macapinlac, H. A., Thompson, P., Basar, R., Nassif Kerbauy, L., Overman, B., Thall, P., Kaplan, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1910607 · Cited by 2,217
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112
CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells
Henn, V., Slupsky, J. R., Gräfe, M., Anagnostopoulos, I., Förster, R., Müller-Berghaus, G., & Kroczek, R. A. (1998) · Nature · doi:10.1038/35393 · Cited by 2,078
KTE-X19 CAR T cell therapy in relapsed or refractory mantle-cell lymphoma
Wang, M., Munoz, J., Goy, A., Locke, F. L., Jacobson, C. A., Hill, B. T., Timmerman, J. M., Holmes, H., Jaglowski, S., Flinn, I. W., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1914347 · Cited by 1,862
Long, A. H., Haso, W. M., Shern, J. F., Wanhainen, K. M., Murgai, M., Ingaramo, M., Smith, J. P., Walker, A. J., Kohler, M. E., Venkateshwara, V. R., et al. (2015) · Nature Medicine · doi:10.1038/nm.3838 · Cited by 1,815
Berdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma.
Raje, N., Berdeja, J., Lin, Y., Siegel, D., Jagannath, S., Madduri, D., Liedtke, M., Rosenblatt, J., Maus, M. V., Turka, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1817226 · Cited by 1,730
DAMP-sensing receptors in sterile inflammation and inflammatory diseases
Gong, T., Liu, L., Jiang, W., & Zhou, R. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0215-7 · Cited by 1,672
The gasdermins, a protein family executing cell death and inflammation
Broz, P., Pelegrín, P., & Shao, F. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-019-0228-2 · Cited by 1,641
Molecular mechanism and function of CD40/CD40L engagement in the immune system
Elgueta, R., Benson, M. J., De Vries, V. C., Wasiuk, A., Guo, Y., & Noelle, R. J. (2009) · Immunological Reviews · doi:10.1111/j.1600-065x.2009.00782.x · Cited by 1,625
Norelli, M., Camisa, B., Barbiera, G., Falcone, L., Purevdorj, A., Genua, M., Sanvito, F., Ponzoni, M., Doglioni, C., Cristofori, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0036-4 · Cited by 1,406
Gust, J., Hay, K. A., Hanafi, L.-A., Li, D., Myerson, D., Gonzalez-Cuyar, L. F., Yeung, C., Liles, W. C., Wurfel, M., Lopez, J. A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0698 · Cited by 1,400
Fry, T. J., Shah, N. N., Orentas, R. J., Stetler-Stevenson, M., Yuan, C. M., Ramakrishna, S., Wolters, P., Martin, S., Delbrook, C., Yates, B., et al. (2018) · Nature Medicine · doi:10.1038/nm.4441 · Cited by 1,335
CAR T cell–induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
Giavridis, T., van der Stegen, S. J. C., Eyquem, J., Hamieh, M., Piersigilli, A., & Sadelain, M. (2018) · Nature Medicine · doi:10.1038/s41591-018-0041-7 · Cited by 1,272
Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy
Morris, E. C., Neelapu, S. S., Giavridis, T., & Sadelain, M. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-021-00547-6 · Cited by 1,104
Santomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
Decade-long leukaemia remissions with persistence of CD4+ CAR T cells
Melenhorst, J. J., Chen, G. M., Wang, M., Porter, D. L., Chen, C., Collins, M. A., Gao, P., Bandyopadhyay, S., Sun, H., Zhao, Z., et al. (2022) · Nature · doi:10.1038/s41586-021-04390-6 · Cited by 923
Zhao, Z., Condomines, M., van der Stegen, S. J. C., Perna, F., Kloss, C. C., Gunset, G., Plotkin, J., & Sadelain, M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.09.004 · Cited by 843
C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
Cermak, J., Key, N., Bach, R., Balla, J., Jacob, H., & Vercellotti, G. (1993) · Blood · doi:10.1182/blood.v82.2.513.513 · Cited by 839
Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo
Rafiq, S., Yeku, O. O., Jackson, H. J., Purdon, T. J., van Leeuwen, D. G., Drakes, D. J., Song, M., Miele, M. M., Li, Z., Wang, P., et al. (2018) · Nature Biotechnology · doi:10.1038/nbt.4195 · Cited by 833
DIVERSE FUNCTIONS OF IL-2, IL-15, AND IL-7 IN LYMPHOID HOMEOSTASIS
Ma, A., Koka, R., & Burkett, P. (2006) · Annual Review of Immunology · doi:10.1146/annurev.immunol.24.021605.090727 · Cited by 829
T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment
Crespo, J., Sun, H., Welling, T. H., Tian, Z., & Zou, W. (2013) · Current Opinion in Immunology · doi:10.1016/j.coi.2012.12.003 · Cited by 752
Hottz, E. D., Azevedo-Quintanilha, I. G., Palhinha, L., Teixeira, L., Barreto, E. A., Pão, C. R. R., Righy, C., Franco, S., Souza, T. M. L., Kurtz, P., et al. (2020) · Blood · doi:10.1182/blood.2020007252 · Cited by 751
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32984-2 · Cited by 739
The blood–brain barrier in systemic infection and inflammation
Galea, I. (2021) · Cellular & Molecular Immunology · doi:10.1038/s41423-021-00757-x · Cited by 738
Remote control of therapeutic T cells through a small molecule–gated chimeric receptor
Wu, C.-Y., Roybal, K. T., Puchner, E. M., Onuffer, J., & Lim, W. A. (2015) · Science · doi:10.1126/science.aab4077 · Cited by 687
Jacobson, C. A., Chavez, J. C., Sehgal, A. R., William, B. M., Munoz, J., Salles, G., Munshi, P. N., Casulo, C., Maloney, D. G., de Vos, S., et al. (2022) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00591-x · Cited by 666
Ruella, M., Xu, J., Barrett, D. M., Fraietta, J. A., Reich, T. J., Ambrose, D. E., Klichinsky, M., Shestova, O., Patel, P. R., Kulikovskaya, I., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0201-9 · Cited by 659
CAR T cell trogocytosis and cooperative killing regulate tumour antigen escape
Hamieh, M., Dobrin, A., Cabriolu, A., van der Stegen, S. J. C., Giavridis, T., Mansilla-Soto, J., Eyquem, J., Zhao, Z., Whitlock, B. M., Miele, M. M., et al. (2019) · Nature · doi:10.1038/s41586-019-1054-1 · Cited by 654
IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors
Cieri, N., Camisa, B., Cocchiarella, F., Forcato, M., Oliveira, G., Provasi, E., Bondanza, A., Bordignon, C., Peccatori, J., Ciceri, F., et al. (2013) · Blood · doi:10.1182/blood-2012-05-431718 · Cited by 625
Sterner, R. M., Sakemura, R., Cox, M. J., Yang, N., Khadka, R. H., Forsman, C. L., Hansen, M. J., Jin, F., Ayasoufi, K., Hefazi, M., et al. (2019) · Blood · doi:10.1182/blood-2018-10-881722 · Cited by 621
Deng, Q., Han, G., Puebla-Osorio, N., Ma, M. C. J., Strati, P., Chasen, B., Dai, E., Dang, M., Jain, N., Yang, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1061-7 · Cited by 600
Ganz, T. (2019) · New England Journal of Medicine · doi:10.1056/nejmra1804281 · Cited by 589
Bernardo, A., Ball, C., Nolasco, L., Moake, J. F., & Dong, J.-F. (2004) · Blood · doi:10.1182/blood-2004-01-0107 · Cited by 588
Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
Hill, J. A., Li, D., Hay, K. A., Green, M. L., Cherian, S., Chen, X., Riddell, S. R., Maloney, D. G., Boeckh, M., & Turtle, C. J. (2018) · Blood · doi:10.1182/blood-2017-07-793760 · Cited by 576
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Orlando, E. J., Han, X., Tribouley, C., Wood, P. A., Leary, R. J., Riester, M., Levine, J. E., Qayed, M., Grupp, S. A., Boyer, M., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0146-z · Cited by 575
Anti-CD22–chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia
Haso, W., Lee, D. W., Shah, N. N., Stetler-Stevenson, M., Yuan, C. M., Pastan, I. H., Dimitrov, D. S., Morgan, R. A., FitzGerald, D. J., Barrett, D. M., et al. (2013) · Blood · doi:10.1182/blood-2012-06-438002 · Cited by 572
Hoyos, V, Savoldo, B., Quintarelli, C., Mahendravada, A., Zhang, M., Vera, J., Heslop, H. E., Rooney, C. M., Brenner, M. K., & Dotti, G. (2010) · Leukemia · doi:10.1038/leu.2010.75 · Cited by 567
Gasdermin E–mediated target cell pyroptosis by CAR T cells triggers cytokine release syndrome
Liu, Y., Fang, Y., Chen, X., Wang, Z., Liang, X., Zhang, T., Liu, M., Zhou, N., Lv, J., Tang, K., et al. (2020) · Science Immunology · doi:10.1126/sciimmunol.aax7969 · Cited by 566
Self-citationCS1, a Potential New Therapeutic Antibody Target for the Treatment of Multiple Myeloma
Hsi, E. D., Steinle, R., Balasa, B., Szmania, S., Draksharapu, A., Shum, B. P., Huseni, M., Powers, D., Nanisetti, A., Zhang, Y., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4246 · Cited by 559
Self-citationTisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
Fowler, N. H., Dickinson, M., Dreyling, M., Martinez-Lopez, J., Kolstad, A., Butler, J., Ghosh, M., Popplewell, L., Chavez, J. C., Bachy, E., et al. (2022) · Nature Medicine · doi:10.1038/s41591-021-01622-0 · Cited by 555
Hartmann, J., Schüßler‐Lenz, M., Bondanza, A., & Buchholz, C. J. (2017) · EMBO Molecular Medicine · doi:10.15252/emmm.201607485 · Cited by 532
Mach, F., Schönbeck, U., Bonnefoy, J.-Y., Pober, J. S., & Libby, P. (1997) · Circulation · doi:10.1161/01.cir.96.2.396 · Cited by 493
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Rejeski, K., Perez, A., Sesques, P., Hoster, E., Berger, C., Jentzsch, L., Mougiakakos, D., Frölich, L., Ackermann, J., Bücklein, V., et al. (2021) · Blood · doi:10.1182/blood.2020010543 · Cited by 475
Shah, N. N., Johnson, B. D., Schneider, D., Zhu, F., Szabo, A., Keever-Taylor, C. A., Krueger, W., Worden, A. A., Kadan, M. J., Yim, S., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-1081-3 · Cited by 468
Alizadeh, D., Wong, R. A., Yang, X., Wang, D., Pecoraro, J. R., Kuo, C.-F., Aguilar, B., Qi, Y., Ann, D. K., Starr, R., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0466 · Cited by 453
Jacoby, E., Nguyen, S. M., Fountaine, T. J., Welp, K., Gryder, B., Qin, H., Yang, Y., Chien, C. D., Seif, A. E., Lei, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms12320 · Cited by 429
Proinflammatory Cytokines Lowering Erythropoietin Production
JELKMANN, W. (1998) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.1998.18.555 · Cited by 422
Samur, M. K., Fulciniti, M., Aktas Samur, A., Bazarbachi, A. H., Tai, Y.-T., Prabhala, R., Alonso, A., Sperling, A. S., Campbell, T., Petrocca, F., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-21177-5 · Cited by 411
Cui, W., Liu, Y., Weinstein, J. S., Craft, J., & Kaech, S. M. (2011) · Immunity · doi:10.1016/j.immuni.2011.09.017 · Cited by 410
Early and late hematologic toxicity following CD19 CAR-T cells
Fried, S., Avigdor, A., Bielorai, B., Meir, A., Besser, M. J., Schachter, J., Shimoni, A., Nagler, A., Toren, A., & Jacoby, E. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0487-3 · Cited by 401
GPRC5D is a target for the immunotherapy of multiple myeloma with rationally designed CAR T cells
Smith, E. L., Harrington, K., Staehr, M., Masakayan, R., Jones, J., Long, T. J., Ng, K. Y., Ghoddusi, M., Purdon, T. J., Wang, X., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aau7746 · Cited by 391
Xu, J., Chen, L.-J., Yang, S.-S., Sun, Y., Wu, W., Liu, Y.-F., Xu, J., Zhuang, Y., Zhang, W., Weng, X.-Q., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819745116 · Cited by 390
Self-citationAnti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma
Ramos, C. A., Grover, N. S., Beaven, A. W., Lulla, P. D., Wu, M.-F., Ivanova, A., Wang, T., Shea, T. C., Rooney, C. M., Dittus, C., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.01342 · Cited by 386
Ramos, C. A., Ballard, B., Zhang, H., Dakhova, O., Gee, A. P., Mei, Z., Bilgi, M., Wu, M.-F., Liu, H., Grilley, B., et al. (2017) · Journal of Clinical Investigation · doi:10.1172/jci94306 · Cited by 375
Self-citationPonomarev, E. D., Shriver, L. P., Maresz, K., Pedras-Vasconcelos, J., Verthelyi, D., & Dittel, B. N. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.1.39 · Cited by 364
Monoclonal antibodies targeting CD 38 in hematological malignancies and beyond
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., Lammerts van Bueren, J. J., Ahmadi, T., Sasser, A. K., Lokhorst, H. M., & Parren, P. W. H. I. (2016) · Immunological Reviews · doi:10.1111/imr.12389 · Cited by 353
Avanzi, M. P., Yeku, O., Li, X., Wijewarnasuriya, D. P., van Leeuwen, D. G., Cheung, K., Park, H., Purdon, T. J., Daniyan, A. F., Spitzer, M. H., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.04.051 · Cited by 341
Wang, C.-M., Wu, Z.-Q., Wang, Y., Guo, Y.-L., Dai, H.-R., Wang, X.-H., Li, X., Zhang, Y.-J., Zhang, W.-Y., Chen, M.-X., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1365 · Cited by 332
Pont, M. J., Hill, T., Cole, G. O., Abbott, J. J., Kelliher, J., Salter, A. I., Hudecek, M., Comstock, M. L., Rajan, A., Patel, B. K. R., et al. (2019) · Blood · doi:10.1182/blood.2019000050 · Cited by 329
Gauthier, J., Hirayama, A. V., Purushe, J., Hay, K. A., Lymp, J., Li, D. H., Yeung, C. C. S., Sheih, A., Pender, B. S., Hawkins, R. M., et al. (2020) · Blood · doi:10.1182/blood.2019002936 · Cited by 328
Weinkove, R., George, P., Dasyam, N., & McLellan, A. D. (2019) · Clinical & Translational Immunology · doi:10.1002/cti2.1049 · Cited by 324
Dai, H., Wu, Z., Jia, H., Tong, C., Guo, Y., Ti, D., Han, X., Liu, Y., Zhang, W., Wang, C., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00856-8 · Cited by 324
Hill, J. A., & Seo, S. K. (2020) · Blood · doi:10.1182/blood.2019004000 · Cited by 305
Pan, J., Tan, Y., Wang, G., Deng, B., Ling, Z., Song, W., Seery, S., Zhang, Y., Peng, S., Xu, J., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.00389 · Cited by 300
Ramos, C. A., Rouce, R., Robertson, C. S., Reyna, A., Narala, N., Vyas, G., Mehta, B., Zhang, H., Dakhova, O., Carrum, G., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.009 · Cited by 299
Self-citationShum, T., Omer, B., Tashiro, H., Kruse, R. L., Wagner, D. L., Parikh, K., Yi, Z., Sauer, T., Liu, D., Parihar, R., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-0538 · Cited by 297
Targeting the T cell receptor β-chain constant region for immunotherapy of T cell malignancies
Maciocia, P. M., Wawrzyniecka, P. A., Philip, B., Ricciardelli, I., Akarca, A. U., Onuoha, S. C., Legut, M., Cole, D. K., Sewell, A. K., Gritti, G., et al. (2017) · Nature Medicine · doi:10.1038/nm.4444 · Cited by 286
Mehta, P., Cron, R. Q., Hartwell, J., Manson, J. J., & Tattersall, R. S. (2020) · The Lancet Rheumatology · doi:10.1016/s2665-9913(20)30096-5 · Cited by 285
The nuclear export protein XPO1 — from biology to targeted therapy
Azmi, A. S., Uddin, M. H., & Mohammad, R. M. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00442-4 · Cited by 279
Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia
Paszkiewicz, P. J., Fräßle, S. P., Srivastava, S., Sommermeyer, D., Hudecek, M., Drexler, I., Sadelain, M., Liu, L., Jensen, M. C., Riddell, S. R., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci84813 · Cited by 276
Park, J. H., Romero, F. A., Taur, Y., Sadelain, M., Brentjens, R. J., Hohl, T. M., & Seo, S. K. (2018) · Clinical Infectious Diseases · doi:10.1093/cid/ciy152 · Cited by 276
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Tong, C., Zhang, Y., Liu, Y., Ji, X., Zhang, W.-Y., Guo, Y., Han, X., Ti, D., Dai, H., Wang, C., et al. (2020) · Blood · doi:10.1182/blood.2020005278 · Cited by 275
Low-Dose Radiation Conditioning Enables CAR T Cells to Mitigate Antigen Escape
DeSelm, C., Palomba, M. L., Yahalom, J., Hamieh, M., Eyquem, J., Rajasekhar, V. K., & Sadelain, M. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.09.008 · Cited by 273
Molecular basis and therapeutic implications of CD40/CD40L immune checkpoint
Tang, T., Cheng, X., Truong, B., Sun, L., Yang, X., & Wang, H. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107709 · Cited by 271
Jain, T., Knezevic, A., Pennisi, M., Chen, Y., Ruiz, J. D., Purdon, T. J., Devlin, S. M., Smith, M., Shah, G. L., Halton, E., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002509 · Cited by 269
Reversible ON- and OFF-switch chimeric antigen receptors controlled by lenalidomide
Jan, M., Scarfò, I., Larson, R. C., Walker, A., Schmidts, A., Guirguis, A. A., Gasser, J. A., Słabicki, M., Bouffard, A. A., Castano, A. P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb6295 · Cited by 267
Neurotoxicity Associated with CD19-Targeted CAR-T Cell Therapies
Gust, J., Taraseviciute, A., & Turtle, C. J. (2018) · CNS Drugs · doi:10.1007/s40263-018-0582-9 · Cited by 264
Cytokines in CAR T Cell–Associated Neurotoxicity
Gust, J., Ponce, R., Liles, W. C., Garden, G. A., & Turtle, C. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.577027 · Cited by 264
Chimeric Antigen Receptor T Cell–Mediated Neurotoxicity in Nonhuman Primates
Taraseviciute, A., Tkachev, V., Ponce, R., Turtle, C. J., Snyder, J. M., Liggitt, H. D., Myerson, D., Gonzalez-Cuyar, L., Baldessari, A., English, C., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1368 · Cited by 256
Diaconu, I., Ballard, B., Zhang, M., Chen, Y., West, J., Dotti, G., & Savoldo, B. (2017) · Molecular Therapy · doi:10.1016/j.ymthe.2017.01.011 · Cited by 250
Bakker, A. B. H., van den Oudenrijn, S., Bakker, A. Q., Feller, N., van Meijer, M., Bia, J. A., Jongeneelen, M. A. C., Visser, T. J., Bijl, N., Geuijen, C. A. W., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1659 · Cited by 247
Role of Platelet P-Selectin and CD40 Ligand in the Induction of Monocytic Tissue Factor Expression
Lindmark, E., Tenno, T., & Siegbahn, A. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.10.2322 · Cited by 245
SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes
Gogishvili, T., Danhof, S., Prommersberger, S., Rydzek, J., Schreder, M., Brede, C., Einsele, H., & Hudecek, M. (2017) · Blood · doi:10.1182/blood-2017-04-778423 · Cited by 243
Kuhn, N. F., Purdon, T. J., van Leeuwen, D. G., Lopez, A. V., Curran, K. J., Daniyan, A. F., & Brentjens, R. J. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.02.006 · Cited by 243
CD22 CAR T-cell therapy in refractory or relapsed B acute lymphoblastic leukemia
Pan, J., Niu, Q., Deng, B., Liu, S., Wu, T., Gao, Z., Liu, Z., Zhang, Y., Qu, X., Zhang, Y., et al. (2019) · Leukemia · doi:10.1038/s41375-019-0488-7 · Cited by 243
The intersection of radiotherapy and immunotherapy: Mechanisms and clinical implications
Spiotto, M., Fu, Y.-X., & Weichselbaum, R. R. (2016) · Science Immunology · doi:10.1126/sciimmunol.aag1266 · Cited by 239
Airoldi, I., Bertaina, A., Prigione, I., Zorzoli, A., Pagliara, D., Cocco, C., Meazza, R., Loiacono, F., Lucarelli, B., Bernardo, M. E., et al. (2015) · Blood · doi:10.1182/blood-2014-09-599423 · Cited by 238
Pan, J., Yang, J. F., Deng, B. P., Zhao, X. J., Zhang, X., Lin, Y. H., Wu, Y. N., Deng, Z. L., Zhang, Y. L., Liu, S. H., et al. (2017) · Leukemia · doi:10.1038/leu.2017.145 · Cited by 235
Self-citationBridging therapy prior to axicabtagene ciloleucel for relapsed/refractory large B-cell lymphoma
Pinnix, C. C., Gunther, J. R., Dabaja, B. S., Strati, P., Fang, P., Hawkins, M. C., Adkins, S., Westin, J., Ahmed, S., Fayad, L., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020001837 · Cited by 230
CD4 Helper and CD8 Cytotoxic T Cell Differentiation
Taniuchi, I. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053411 · Cited by 225
van Mierlo, G. J. D., den Boer, A. T., Medema, J. P., van der Voort, E. I. H., Fransen, M. F., Offringa, R., Melief, C. J. M., & Toes, R. E. M. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.082107699 · Cited by 222
A bispecific CAR-T cell therapy targeting BCMA and CD38 in relapsed or refractory multiple myeloma
Mei, H., Li, C., Jiang, H., Zhao, X., Huang, Z., Jin, D., Guo, T., Kou, H., Liu, L., Tang, L., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01170-7 · Cited by 222
CD70-specific CAR T cells have potent activity against acute myeloid leukemia without HSC toxicity
Sauer, T., Parikh, K., Sharma, S., Omer, B., Sedloev, D., Chen, Q., Angenendt, L., Schliemann, C., Schmitt, M., Müller-Tidow, C., et al. (2021) · Blood · doi:10.1182/blood.2020008221 · Cited by 219
Gamma-Delta CAR-T Cells Show CAR-Directed and Independent Activity Against Leukemia
Rozenbaum, M., Meir, A., Aharony, Y., Itzhaki, O., Schachter, J., Bank, I., Jacoby, E., & Besser, M. J. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01347 · Cited by 218
Curran, K. J., Seinstra, B. A., Nikhamin, Y., Yeh, R., Usachenko, Y., van Leeuwen, D. G., Purdon, T., Pegram, H. J., & Brentjens, R. J. (2015) · Molecular Therapy · doi:10.1038/mt.2015.4 · Cited by 217
Pfeiffer, A., Thalheimer, F. B., Hartmann, S., Frank, A. M., Bender, R. R., Danisch, S., Costa, C., Wels, W. S., Modlich, U., Stripecke, R., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809158 · Cited by 212
Riether, C., Pabst, T., Höpner, S., Bacher, U., Hinterbrandner, M., Banz, Y., Müller, R., Manz, M. G., Gharib, W. H., Francisco, D., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0910-8 · Cited by 207
Chimeric antigen receptor T cell persistence and memory cell formation
McLellan, A. D., & Ali Hosseini Rad, S. M. (2019) · Immunology & Cell Biology · doi:10.1111/imcb.12254 · Cited by 206
Wang, D., Wang, J., Hu, G., Wang, W., Xiao, Y., Cai, H., Jiang, L., Meng, L., Yang, Y., Zhou, X., et al. (2021) · Blood · doi:10.1182/blood.2020008936 · Cited by 204
Self-citationJetani, H., Garcia-Cadenas, I., Nerreter, T., Thomas, S., Rydzek, J., Meijide, J. B., Bonig, H., Herr, W., Sierra, J., Einsele, H., et al. (2018) · Leukemia · doi:10.1038/s41375-018-0009-0 · Cited by 203
Pivotal Roles of GM‐CSF in Autoimmunity and Inflammation
Shiomi, A., & Usui, T. (2015) · Mediators of Inflammation · doi:10.1155/2015/568543 · Cited by 201
CAR-T cells targeting CLL-1 as an approach to treat acute myeloid leukemia
Wang, J., Chen, S., Xiao, W., Li, W., Wang, L., Yang, S., Wang, W., Xu, L., Liao, S., Liu, W., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0553-5 · Cited by 201
Self-citationStrati, P., Ahmed, S., Kebriaei, P., Nastoupil, L. J., Claussen, C. M., Watson, G., Horowitz, S. B., Brown, A. R. T., Do, B., Rodriguez, M. A., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002328 · Cited by 201
Wang, Y., Zhang, W.-Y., Han, Q.-W., Liu, Y., Dai, H.-R., Guo, Y.-L., Bo, J., Fan, H., Zhang, Y., Zhang, Y.-J., et al. (2014) · Clinical Immunology · doi:10.1016/j.clim.2014.10.002 · Cited by 194
Baird, J. H., Epstein, D. J., Tamaresis, J. S., Ehlinger, Z., Spiegel, J. Y., Craig, J., Claire, G. K., Frank, M. J., Muffly, L., Shiraz, P., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020002732 · Cited by 193
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Tambaro, F. P., Singh, H., Jones, E., Rytting, M., Mahadeo, K. M., Thompson, P., Daver, N., DiNardo, C., Kadia, T., Garcia-Manero, G., et al. (2021) · Leukemia · doi:10.1038/s41375-021-01232-2 · Cited by 193
Guo, B., Chen, M., Han, Q., Hui, F., Dai, H., Zhang, W., Zhang, Y., Wang, Y., Zhu, H., & Han, W. (2016) · Journal of Cellular Immunotherapy · doi:10.1016/j.jocit.2014.11.001 · Cited by 191
Ruella, M., Klichinsky, M., Kenderian, S. S., Shestova, O., Ziober, A., Kraft, D. O., Feldman, M., Wasik, M. A., June, C. H., & Gill, S. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0850 · Cited by 191
In Vivo Generation of CAR T Cells Selectively in Human CD4+ Lymphocytes
Agarwal, S., Hanauer, J. D. S., Frank, A. M., Riechert, V., Thalheimer, F. B., & Buchholz, C. J. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.05.005 · Cited by 191
Myers, R. M., Li, Y., Barz Leahy, A., Barrett, D. M., Teachey, D. T., Callahan, C., Fasano, C. C., Rheingold, S. R., DiNofia, A., Wray, L., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03458 · Cited by 190
Danese, S., de la Motte, C., Reyes, B. M. R., Sans, M., Levine, A. D., & Fiocchi, C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.4.2011 · Cited by 189
Drent, E., Groen, R. W. J., Noort, W. A., Themeli, M., Lammerts van Bueren, J. J., Parren, P. W. H. I., Kuball, J., Sebestyen, Z., Yuan, H., de Bruijn, J., et al. (2016) · Haematologica · doi:10.3324/haematol.2015.137620 · Cited by 186
Prommersberger, S., Reiser, M., Beckmann, J., Danhof, S., Amberger, M., Quade-Lyssy, P., Einsele, H., Hudecek, M., Bonig, H., & Ivics, Z. (2021) · Gene Therapy · doi:10.1038/s41434-021-00254-w · Cited by 182
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021
Zelenetz, A. D., Gordon, L. I., Chang, J. E., Christian, B. A., Abramson, J. S., Advani, R. H., Bartlett, N. L., Budde, L. E., Caimi, P. F., de Vos, S., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0054 · Cited by 182
Kikushige, Y., Yoshimoto, G., Miyamoto, T., Iino, T., Mori, Y., Iwasaki, H., Niiro, H., Takenaka, K., Nagafuji, K., Harada, M., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.11.7358 · Cited by 181
Hu, Y., Sun, J., Wu, Z., Yu, J., Cui, Q., Pu, C., Liang, B., Luo, Y., Shi, J., Jin, A., et al. (2016) · Journal of Hematology & Oncology · doi:10.1186/s13045-016-0299-5 · Cited by 178
An APRIL-based chimeric antigen receptor for dual targeting of BCMA and TACI in multiple myeloma
Lee, L., Draper, B., Chaplin, N., Philip, B., Chin, M., Galas-Filipowicz, D., Onuoha, S., Thomas, S., Baldan, V., Bughda, R., et al. (2018) · Blood · doi:10.1182/blood-2017-05-781351 · Cited by 174
4-1BB enhancement of CAR T function requires NF-κB and TRAFs
Li, G., Boucher, J. C., Kotani, H., Park, K., Zhang, Y., Shrestha, B., Wang, X., Guan, L., Beatty, N. J., Abate‐Daga, D., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.121322 · Cited by 171
CAR T-cell therapy for multiple myeloma: state of the art and prospects
van de Donk, N. W. C. J., Usmani, S. Z., & Yong, K. (2021) · The Lancet Haematology · doi:10.1016/s2352-3026(21)00057-0 · Cited by 170
The immune landscape and response to immune checkpoint blockade therapy in lymphoma
Kline, J., Godfrey, J., & Ansell, S. M. (2020) · Blood · doi:10.1182/blood.2019000847 · Cited by 167
Juluri, K. R., Wu, Q. V., Voutsinas, J. M., Hou, J., Hirayama, A. V. V., Mullane, E., Miles, N., Maloney, D. G., Turtle, C. J., Bar, M., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2020004142 · Cited by 167
Zhang, Q., Hresko, M. E., Picton, L. K., Su, L., Hollander, M. J., Nuñez-Cruz, S., Zhang, Z., Assenmacher, C., Sockolosky, J. T., García, K. C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg6986 · Cited by 167
Wermke, M., Kraus, S., Ehninger, A., Bargou, R. C., Goebeler, M.-E., Middeke, J. M., Kreissig, C., von Bonin, M., Koedam, J., Pehl, M., et al. (2021) · Blood · doi:10.1182/blood.2020009759 · Cited by 165
Lanitis, E., Rota, G., Kosti, P., Ronet, C., Spill, A., Seijo, B., Romero, P., Dangaj, D., Coukos, G., & Irving, M. (2021) · Journal of Experimental Medicine · doi:10.1084/jem.20192203 · Cited by 163
Sim, A. J., Jain, M. D., Figura, N. B., Chavez, J. C., Shah, B. D., Khimani, F., Lazaryan, A., Krivenko, G., Davila, M. L., Liu, H. D., et al. (2019) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2019.05.065 · Cited by 162
Roselli, E., Boucher, J. C., Li, G., Kotani, H., Spitler, K., Reid, K. M., Cervantes, E. V., Bulliard, Y., Tu, N., Lee, S. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003354 · Cited by 162
Liu, S., Deng, B., Yin, Z., Pan, J., Lin, Y., Ling, Z., Wu, T., Chen, D., Chang, A. H., Gao, Z., et al. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-0280-y · Cited by 161
Sachdeva, M., Duchateau, P., Depil, S., Poirot, L., & Valton, J. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ac119.007558 · Cited by 159
Cao, Y., Lu, W., Sun, R., Jin, X. K., Cheng, L., He, X., Wang, L., Yuan, T., Lyu, C., & Zhao, M. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00767 · Cited by 157
Strati, P., Varma, A., Adkins, S., Nastoupil, L. J., Westin, J. R., Hagemeister, F. B., Fowler, N. H., Lee, H. J., Fayad, L., Samaniego, F., et al. (2020) · Haematologica · doi:10.3324/haematol.2020.254045 · Cited by 155
Schneider, D., Xiong, Y., Wu, D., Hu, P., Alabanza, L. M., Steimle, B. L., Mahmud, H., Anthony-Gonda, K., Krueger, W. H., Zhu, Z., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc6401 · Cited by 155
Eriksson, E., Milenova, I. E., Wenthe, J., Ståhle, M., Leja-Jarblad, J., Ullenhag, G. J., Dimberg, A., Moreno, R., Alemany, R., & Loskog, A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0285 · Cited by 154
Monocyte lineage–derived IL-6 does not affect chimeric antigen receptor T-cell function
Singh, N., Hofmann, T. J., Gershenson, Z., Levine, B. L., Grupp, S. A., Teachey, D. T., & Barrett, D. M. (2017) · Cytotherapy · doi:10.1016/j.jcyt.2017.04.001 · Cited by 151
Zhou, J., Jin, L., Wang, F., Zhang, Y., Liu, B., & Zhao, T. (2019) · Protein & Cell · doi:10.1007/s13238-019-0643-y · Cited by 151
The model of cytokine release syndrome in CAR T-cell treatment for B-cell non-Hodgkin lymphoma
Wei, J., Liu, Y., Wang, C., Zhang, Y., Tong, C., Dai, G., Wang, W., Rasko, J. E. J., Melenhorst, J. J., Qian, W., et al. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00256-x · Cited by 149
Wehrli, M., Gallagher, K., Chen, Y., Leick, M. B., McAfee, S. L., El-Jawahri, A. R., DeFilipp, Z. M., Horick, N., O’Donnell, P. V., Spitzer, T. R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003847 · Cited by 147
Olejniczak, S. H., Stewart, C. C., Donohue, K. A., & Czuczman, M. S. (2006) · Immunological Investigations · doi:10.1080/08820130500496878 · Cited by 145
A Novel Anti-LILRB4 CAR-T Cell for the Treatment of Monocytic AML
John, S., Chen, H., Deng, M., Gui, X., Wu, G., Chen, W., Li, Z., Zhang, N., An, Z., & Zhang, C. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.08.001 · Cited by 145
Gill, S. I., Vides, V., Frey, N. V., Hexner, E. O., Metzger, S. T., O'Brien, M., Hwang, W., Brogdon, J. L., Suhoski, M. M., Fraietta, J. A., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007317 · Cited by 143
Alcantara, M., Tesio, M., June, C. H., & Houot, R. (2018) · Leukemia · doi:10.1038/s41375-018-0285-8 · Cited by 142
Improving the safety of CAR-T cell therapy by controlling CRS-related coagulopathy
Jiang, H., Liu, L., Guo, T., Wu, Y., Ai, L., Deng, J., Dong, J. W., Mei, H., & Hu, Y. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03685-z · Cited by 141
Obstfeld, A. E., Frey, N. V., Mansfield, K. G., Lacey, S. F., June, C. H., Porter, D. L., Melenhorst, J. J., & Wasik, M. A. (2017) · Blood · doi:10.1182/blood-2017-08-802413 · Cited by 140
Cui, Q., Qian, C., Xu, N., Kang, L., Dai, H., Cui, W., Song, B., Yin, J., Li, Z., Zhu, X., et al. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01092-4 · Cited by 135
Blockade of PD-1 immunosuppression boosts CAR T-cell therapy
John, L. B., Kershaw, M. H., & Darcy, P. K. (2013) · OncoImmunology · doi:10.4161/onci.26286 · Cited by 134
Selinexor: First Global Approval
Syed, Y. Y. (2019) · Drugs · doi:10.1007/s40265-019-01188-9 · Cited by 131
Lança, T., Correia, D. V., Moita, C. F., Raquel, H., Neves‐Costa, A., Ferreira, C., Ramalho, J. S., Barata, J. T., Moita, L. F., Gomes, A. Q., et al. (2010) · Blood · doi:10.1182/blood-2009-08-237123 · Cited by 128
Schmidts, A., Ormhøj, M., Choi, B. D., Taylor, A., Bouffard, A. A., Scarfò, I., Larson, R. C., Frigault, M. J., Gallagher, K., Castaño, A. P., et al. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000703 · Cited by 122
Pinz, K. G., Liu, H.-L., Golightly, M. G., Jares, A., Lan, F., Zieve, G. W., Hagag, N. G., Schuster, M., Firor, A. E., Jiang, X., et al. (2015) · Leukemia · doi:10.1038/leu.2015.311 · Cited by 120
The potential role of γδ T cells after allogeneic HCT for leukemia
Handgretinger, R., & Schilbach, K. (2018) · Blood · doi:10.1182/blood-2017-08-752162 · Cited by 120
CD40 stimulation as a molecular adjuvant for cancer vaccines and other immunotherapies
Bullock, T. N. J. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00734-4 · Cited by 118
Siglec-6 is a novel target for CAR T-cell therapy in acute myeloid leukemia
Jetani, H., Navarro‐Bailón, A., Maucher, M., Frenz, S., Verbruggen, C., Yeguas, A., Vídriales, M., González, M., Saborido, J. R., Kraus, S., et al. (2021) · Blood · doi:10.1182/blood.2020009192 · Cited by 118
Loschinski, R., Böttcher, M., Stoll, A., Bruns, H., Mackensen, A., & Mougiakakos, D. (2018) · Oncotarget · doi:10.18632/oncotarget.24442 · Cited by 115
Macrophage, the potential key mediator in CAR-T related CRS
Hao, Z., Li, R., Li, M., Han, Z., & Hong, Z. (2020) · Experimental Hematology and Oncology · doi:10.1186/s40164-020-00171-5 · Cited by 115
Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia
Khawanky, N. E., Hughes, A., Yu, W., Myburgh, R., Matschulla, T., Taromi, S., Aumann, K., Clarson, J., Vinnakota, J. M., Shoumariyeh, K., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26683-0 · Cited by 112
Tumor cell recognition by γδ T lymphocytes
Correia, D. V., Lopes, A. C., & Silva‐Santos, B. (2013) · OncoImmunology · doi:10.4161/onci.22892 · Cited by 111
Wang, Y., Qi, K., Cheng, H., Cao, J., Shi, M., Qiao, J., Yan, Z., Jing, G., Pan, B., Sang, W., et al. (2019) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2019.11.027 · Cited by 110
Sommer, C., Cheng, H., Nguyen, D., Dettling, D. E., Yeung, Y. A., Sutton, J. E., Hamze, M., Valton, J., Smith, J. N. P., Djuretic, I. M., et al. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.022 · Cited by 108
Li, S., Wang, X., Yuan, Z., Liu, L., Luo, L., Li, Y., Wu, K., Liu, J., Yang, C., Li, Z., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-1271 · Cited by 108
FDA Approval Summary: Idecabtagene Vicleucel for Relapsed or Refractory Multiple Myeloma
Sharma, P., Kanapuru, B., George, B., Lin, X., Xu, Z., Bryan, W. W., Pazdur, R., & Theoret, M. R. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-3803 · Cited by 108
A BAFF ligand-based CAR-T cell targeting three receptors and multiple B cell cancers
Wong, D. P., Roy, N. K., Zhang, K., Anukanth, A., Asthana, A., Shirkey, N. J., Dunmire, S. K., Jones, B. J., Lahr, W. S., Webber, B. R., et al. (2022) · Nature Communications · doi:10.1038/s41467-021-27853-w · Cited by 107
The Bone Marrow Microenvironment Mechanisms in Acute Myeloid Leukemia
Pimenta, D. B., Varela, V. A., Datoguia, T. S., Caraciolo, V. B., Lopes, G. H., & Pereira, W. O. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.764698 · Cited by 106
Rapidly Switchable Universal CAR-T Cells for Treatment of CD123-Positive Leukemia
Loff, S., Dietrich, J., Meyer, J.-E., Riewaldt, J., Spehr, J., Bonin, M. V., Gründer, C., Swayampakula, M., Franke, K., Feldmann, A., et al. (2020) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2020.04.009 · Cited by 105
Wright, C. M., Lariviere, M. J., Baron, J. A., Uche, C. Z., Xiao, Y., Arscott, W. T., Anstadt, E. J., Barsky, A. R., Miller, D., LaRose, M. I., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.05.014 · Cited by 104
Self-citationSun, C., Mahendravada, A., Ballard, B. C., Kale, B. J., Ramos, C. A., West, J., Maguire, T., McKay, K., Lichtman, E. I., Tuchman, S. A., et al. (2019) · Oncotarget · doi:10.18632/oncotarget.26792 · Cited by 103
Liadi, I., Singh, H., Romain, G., Rey-Villamizar, N., Merouane, A., Adolacion, J. R. T., Kebriaei, P., Huls, H. M., Qiu, P., Roysam, B., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0195 · Cited by 102
A Bump in the Road: How the Hostile AML Microenvironment Affects CAR T Cell Therapy
Epperly, R., Gottschalk, S. M., & Velasquez, M. P. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00262 · Cited by 101
Duan, D., Wang, K., Cheng, W., Feng, D., Liu, Y., He, Q., Xu, X., Wang, C., Zhao, S., Lv, L., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.609421 · Cited by 98
Smith, E. L., Mailankody, S., Stæhr, M., Wang, X., Sénéchal, B., Purdon, T. J., Daniyan, A. F., Geyer, M. B., Goldberg, A. D., Mead, E., et al. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0551 · Cited by 96
Works, M. G., Soni, N., Hauskins, C., Sierra, C., Baturevych, A., Jones, J. C., Curtis, W., Carlson, P., Johnstone, T. G., Kugler, D. G., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-18-1146 · Cited by 93
Sridharan, V., Margalit, D. N., Lynch, S. A., Severgnini, M., Zhou, J. M., Chau, N. G., Rabinowits, G., Lorch, J. H., Hammerman, P. S., Hodi, F. S., et al. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.166 · Cited by 92
CNS Endothelial Cell Activation Emerges as a Driver of CAR T Cell–Associated Neurotoxicity
Mackall, C. L., & Miklos, D. B. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1084 · Cited by 91
Johnsrud, A. J., Craig, J. K., Baird, J. H., Spiegel, J. Y., Muffly, L. S., Zehnder, J. L., Tamaresis, J. S., Negrin, R. S., Johnston, L., Arai, S., et al. (2021) · Blood Advances · doi:10.1182/bloodadvances.2021004716 · Cited by 91
Tang, Y., Yin, H., Zhao, X., Jin, D., Liang, Y., Xiong, T., Li, L., Tang, W., Zhang, J., Liu, M., et al. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-02214-z · Cited by 89
Aspuria, P.-J. P., Vivona, S., Bauer, M., Semana, M., Ratti, N. P., McCauley, S., Riener, R. M., Malefyt, R. D. W., Rokkam, D., Emmerich, J., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abg7565 · Cited by 88
Li, C., Cao, W., Que, Y., Wang, Q., Xiao, Y., Gu, C., Wang, D., Wang, J., Jiang, L., Xu, H., et al. (2021) · Clinical and Translational Medicine · doi:10.1002/ctm2.346 · Cited by 87
Self-citationYou, L., Han, Q., Zhu, L., Zhu, Y., Bao, C., Yang, C., Lei, W., & Qian, W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01787 · Cited by 86
Self-citationSang, W., Shi, M., Yang, J., Cao, J., Xu, L., Yan, D., Yao, M., Liu, H., Li, W., Zhang, B., et al. (2020) · Cancer Medicine · doi:10.1002/cam4.3259 · Cited by 85
Wei, G., Zhang, Y., Zhao, H., Wang, Y., Liu, Y., Liang, B., Wang, X., Xu, H., Cui, J., Wu, W., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0675 · Cited by 85
Song, M.-K., Park, B.-B., & Uhm, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061326 · Cited by 79
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide
Radhakrishnan, S. V., Luetkens, T., Scherer, S. D., Davis, P. M., Mause, E. R. V., Olson, M., Yousef, S., Panse, J., Abdiche, Y. N., Li, K. D., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14619-z · Cited by 79
Xie, G., Ivica, N. A., Jia, B., Li, Y., Dong, H., Liang, Y., Brown, D. R., Romee, R., & Chen, J. (2020) · Nature Biomedical Engineering · doi:10.1038/s41551-020-00625-5 · Cited by 79
Human γδ T-Cells: From Surface Receptors to the Therapy of High-Risk Leukemias
Pistoia, V., Tumino, N., Vacca, P., Veneziani, I., Moretta, A., Locatelli, F., & Moretta, L. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00984 · Cited by 78
Luo, H., Wang, N., Huang, L., Zhou, X., Jin, J., Li, C., Wang, D., Xu, B., Xu, J., Jiang, L., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0767-x · Cited by 78
Self-citationTreatment of Aggressive T Cell Lymphoblastic Lymphoma/leukemia Using Anti-CD5 CAR T Cells
Feng, J., Xu, H.-C., Cinquina, A., Wu, Z., Chen, Q., Zhang, P., Wang, X., Shan, H., Xu, L., Zhang, Q., et al. (2021) · Stem Cell Reviews and Reports · doi:10.1007/s12015-020-10092-9 · Cited by 77
Self-citationSong, W., & Zhang, M. (2020) · Clinical Immunology · doi:10.1016/j.clim.2020.108382 · Cited by 75
Holthof, L. C., & Mutis, T. (2020) · Cancers · doi:10.3390/cancers12040988 · Cited by 74
Guercio, M., Orlando, D., Cecca, S. D., Sinibaldi, M., Boffa, I., Caruso, S., Abbaszadeh, Z., Camera, A., Cembrola, B., Bovetti, K., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.231183 · Cited by 73
Immune checkpoint inhibitors in lymphoma: challenges and opportunities
Hatic, H., Sampat, D., & Goyal, G. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-6833 · Cited by 72
Jain, M. D., & Davila, M. L. (2017) · Stem Cells · doi:10.1002/stem.2715 · Cited by 71
41BB-based and CD28-based CD123-redirected T-cells ablate human normal hematopoiesis in vivo
Baroni, M. L., Sánchez‐Martínez, D., Gutiérrez‐Agüera, F., Roca-Ho, H., Castellà, M., Zanetti, S. R., Velasco-Hernández, T., de la Guardia, R. D., Castaño, J., Anguita, E., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000845 · Cited by 71
Metadata
- Authors
- Zhang, X., Zhu, L., Zhang, H., Chen, S., & Xiao, Y.
- Venue
- Frontiers in Immunology
- Publisher
- Frontiers Media SA
- Published
- 2022-06-10
- Volume
- 13
- Pages
- 927153-927153
- ISSN
- 1664-3224 (ISSN-L)
- OpenAlex
- W4281961745
- Cited by
- 396
- References
- 256
- FWCI
- 28.28
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.